Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Osteoporosis International
Erschienen in: Osteoporosis International 10/2015

01.10.2015 | Original Article

Taxonomy of rare genetic metabolic bone disorders

verfasst von: L. Masi, D. Agnusdei, J. Bilezikian, D. Chappard, R. Chapurlat, L. Cianferotti, J.-P. Devolgelaer, A. El Maghraoui, S. Ferrari, M. K. Javaid, J.-M. Kaufman, U. A. Liberman, G. Lyritis, P. Miller, N. Napoli, E. Roldan, S. Papapoulos, N. B. Watts, M. L. Brandi

Erschienen in: Osteoporosis International | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Summary

This article reports a taxonomic classification of rare skeletal diseases based on metabolic phenotypes. It was prepared by The Skeletal Rare Diseases Working Group of the International Osteoporosis Foundation (IOF) and includes 116 OMIM phenotypes with 86 affected genes.

Introduction

Rare skeletal metabolic diseases comprise a group of diseases commonly associated with severe clinical consequences. In recent years, the description of the clinical phenotypes and radiographic features of several genetic bone disorders was paralleled by the discovery of key molecular pathways involved in the regulation of bone and mineral metabolism. Including this information in the description and classification of rare skeletal diseases may improve the recognition and management of affected patients.

Methods

IOF recognized this need and formed a Skeletal Rare Diseases Working Group (SRD-WG) of basic and clinical scientists who developed a taxonomy of rare skeletal diseases based on their metabolic pathogenesis.

Results

This taxonomy of rare genetic metabolic bone disorders (RGMBDs) comprises 116 OMIM phenotypes, with 86 affected genes related to bone and mineral homeostasis. The diseases were divided into four major groups, namely, disorders due to altered osteoclast, osteoblast, or osteocyte activity; disorders due to altered bone matrix proteins; disorders due to altered bone microenvironmental regulators; and disorders due to deranged calciotropic hormonal activity.

Conclusions

This article provides the first comprehensive taxonomy of rare metabolic skeletal diseases based on deranged metabolic activity. This classification will help in the development of common and shared diagnostic and therapeutic pathways for these patients and also in the creation of international registries of rare skeletal diseases, the first step for the development of genetic tests based on next generation sequencing and for performing large intervention trials to assess efficacy of orphan drugs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Ayme S, Schmidtke J (2007) Networking for rare diseases: a necessity for Europe. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 50:1477–1483CrossRef
3.
4.
Haffner ME, Whitley J, Moses M (2002) Two decades of orphan product development. Nat Rev Drug Discov 10:821–825CrossRef
5.
Braun MM, Farag-El-Massah S, Xu K, Coté TR (2010) Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nature Reviews Drug Discovery 9:519–522PubMed
6.
7.
Villa S, Compagni A, Reich MR (2009) Orphan drug legislation: lessons for neglected tropical diseases. Int J Health Plann Manage 24:27–42CrossRefPubMed
8.
(2010) 5th European conference on rare diseases. European reference networks & centers of expertise for rare diseases, pp. 1–75
9.
10.
Commission Regulation (EC) No 847/2000 of 27 April 2000; OJ L 103, 28.4.2000
11.
12.
13.
14.
Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal product’ and ‘clinical superiority’. Off J Eur Commun 103/5-103/8
15.
16.
Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA (2012) What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis. Pediatrics 129:516–521CrossRefPubMed
17.
Forman J, Taruscio D, Llera VA, Barrera LA, Coté TR, Edfjall C, Gahved D, Haffner ME, Nishimura Y, Posada M, Tambuyzer E, Groft SC, Henter J-I (2012) The need for world-wide policy and actions plans for rare diseases. Acta Pediatr 101:805–807CrossRef
18.
Roldán EJA (2013) Proceedings from the VIII International Conference on Rare Diseases and Orphan Drugs (ICORD), St Petersburg (Russia). Rare J 1(suppl 1):1–48
19.
Mäkitie O (2011) Molecular defects causing skeletal dysplasias. Camacho-Hübner C, Nilsson O, SŠvendahl L (eds) Cartilage and bone development and its disorders. Endocr Dev. Basel, Karger, vol 21, pp 78–84
20.
(1970) International nomenclature of constitutional diseases of bones. Ann Radiol (Paris) 13(7):455–464
21.
(1971a) A nomenclature for constitutional (intrinsic) diseases of bones. J Pediatr 78(1):177–179
22.
(1971b) International nomenclature of constitutional bone diseases. Constitutional bone diseases without known pathogenesis. Arch Fr Pediatr 28(5):553–557
23.
Nomenclature for constitutional (intrinsic) diseases of bones. (1971c) Pediatrics 47(2):431–344. Nomenclature for the constitutional (intrinsic) diseases of bone. Radiology. 1971d; 99(3):699–702
24.
McKusick VA, Scott CI (1971) A nomenclature for constitutional disorders of bone. J Bone Joint Surg Am 53(5):978–986PubMed
25.
Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabe B, Superti-Furga A (2011) Nosology and classification of genetic skeletal disorders—2010 revision. Am J Med Genet A 155A(5):943–968CrossRefPubMed
26.
Superti-Furga A, Unger S (2007) Nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet A 143(1):1–18CrossRef
27.
Boyce BF, Zuscik MJ, Xing L (2013) Biology of bone and cartilage. In: Thakker RV, Whyte MP, Eisman JA, Igarashi T (eds) 1 edn. Genetics of bone biology and skeletal diseases. Ch. 1 pp. 3–24
28.
Pagani F, Francucci CM, Moro L (2005) Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest 28:8–13CrossRefPubMed
29.
Berndt TJ, Schiavi S, Kumar R (2005) Phosphatonins and the regulation of phosphorus homeostasis. Am J Renal Physiol 289:1170–1182CrossRef
30.
Kumar R, Riggs R (1980) Pathologic bone physiology. In: Urist MR (ed) Fundamental and clinical bone physiology. Lippincott, Philadelphia, pp 394–406
31.
Schiavi SC, Moe OW (2002) Phosphatonins: a new class of phosphate regulating proteins. Curr Opin Nephrol Hypertens 11:423–430CrossRefPubMed
32.
Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239–297PubMed
33.
Alfadda TI, Saleh AM, Houllier P, Gaidel JP (2014) Calcium-sensing receptor 20 years later. Am J Physiol 307(3):C221–C231CrossRef
34.
Kumar R (1990) Vitamin D metabolism and mechanisms of calcium transport. J Am Soc Nephrol 1:30–42PubMed
35.
Fleisch H (1980) Homeostasis of inorganic phosphate. In: Urist MR (ed) Fundamental and clinical bone physiology. Lippincott, Philadelphia, pp 268–282
36.
Burtis WJ, Wu T, Bunch C, Wysolmerski JJ, Insogna KL, Weir EC, Broadus AE, Stewart AF (1987) Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem 262:7151–7156PubMed
37.
Kronenberg HM (2003) Developmental regulation of the growth plate. Nature 2423:332–336CrossRef
38.
Juppner H, Silve C (2013) Genetic disorders affecting PTH/PTHrP receptor function. In: Thakker RV, Whyte MP, Eisman JA, Igarashi T (eds) Genetics of bone biology and skeletal diseases. Ch. 28, pp. 441–457
39.
Qin C, Baba O, Butler WT (2004) Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 15:126–136CrossRefPubMed
40.
Econs MJ, Drezner MK (1994) Tumor induced osteomalacia unveiling a new hormone. N Engl J Med 330:1679–1681CrossRefPubMed
41.
Quarles LD (2003) FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285:E1–9CrossRefPubMed
42.
43.
Fukuchi M, Fukai Y, Masuda N, Miyazaki T, Nakajima M, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H (2002) High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 62:7162–7165PubMed
44.
Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292–304CrossRefPubMed
45.
Hofbauer LC, Kühne CA, Viereck V (2004) The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4:268–75PubMed
46.
Henriksen K, Bollerslev J, Everts V, Karsdal MA (2011) Osteoclast activity and subtypes as a function of physiology and pathology—implications for future treatments of osteoporosis. Endocrine Reviews 32:31–63CrossRefPubMed
47.
Ross PF (2013) Osteoclast biology and bone resorption. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. Official publication of the American Society for Bone and Mineral Research (ASBMR) 8 edn Ch. 3 pp.25–33
48.
Blair HC, Teitelbaum SL, Ghiselli R, Gluck S (1989) Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855–857CrossRefPubMed
49.
Blair HC, Teitelbaum SL, Tan HL, Koziol CM, Schlesinger PH (1991) Passive chloride permeability charge coupled to H(+)-ATPase of avian osteoclast ruffled membrane. Am J Physiol 260:C1315–C1324PubMed
50.
Josephsen K, Praetorius J, Frische S, Gawenis LR, Kwon TH, Agre P, Nielsen S, Fejerskov O (2009) Targeted disruption of the Cl/HCO3 exchanger Ae2 results in osteopetrosis in mice. Proc Natl Acad Sci USA 106:1638–1641PubMedCentralCrossRefPubMed
51.
Baron R, Neff L, Louvard D, Courtoy PJ (1985) Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 101:2210–2222CrossRefPubMed
52.
Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L, Notarangelo LD, Vezzoni P, Villa A (2000) Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 25:343–346CrossRefPubMed
53.
Karsdal MA, Henriksen K, Sørensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467–47PubMedCentralCrossRefPubMed
54.
Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J, Karsdal MA (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537–1545PubMedCentralCrossRefPubMed
55.
Arnett TA (2008) Extracellular pH regulates bone cell function. J Nutr 138:415S–418SPubMed
56.
57.
Jansen ID, Mardones P, Lecanda F, de Vries TJ, Recalde S, Hoeben KA, Schoenmaker T, Ravesloot JH, van Borren MM, van Eijden TM, Bronckers AL, Kellokumpu S, Medina JF, Everts V, Oude Elferink RP (2009) Ae2a, b-deficient mice exhibit osteopetrosis of long bones but not of calvaria. FASEB J 23:3470–3481CrossRefPubMed
58.
Gowen M, Lazner F, Dodds R, Kapadia R, Field J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I (1999) Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654–1663CrossRefPubMed
59.
Calvo MS, Eyre DR, Gundberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17:333–368PubMed
60.
Singer FR, Eyre MD (2008) Using biochemical markers of bone turnover in clinical practice. Cleveland Clinic Journal of Medicine 75:739–750CrossRefPubMed
61.
Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY (2009) Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 63:19–26PubMedCentralCrossRefPubMed
62.
Suwanwalaikorn S, Van Auken M, Kang MI, Alex S, Braverman LE, Baran DT (1997) Site selectivity of osteoblast gene expression response to thyroid hormone localized by in situ hybridization. Am J Physiol 272(2 Pt 1):E212–217PubMed
63.
Kasperk C, Wergedal J, Strong D, Farley J, Wangerin K, Gropp H, Ziegler R, Baylink DJ (1995) Human bone cell phenotypes differ depending on their skeletal site of origin. J Clin Endocrinol Metab 80(8):2511–2517PubMed
64.
Orimo H (2010) The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch 77:4–12CrossRefPubMed
65.
Mortland M, Robison R (1929) The preparation and use of the phosphatase. Biochem J 23:237–242CrossRef
66.
Seibel MJ (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26:97–122PubMedCentralPubMed
67.
Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF (1985) Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 60:736–739CrossRefPubMed
68.
Delmas PD, Wilson DM, Mann KG, Riggs BL (1983) Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 57:1028–1030CrossRefPubMed
69.
Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Reginster JY, Gangji V, Members of Advisory Board on Bone Markers (2009) Evidence-based guidelines for the use of biochemical markers, bone turnover: biomarkers of bone turnover. Int J Clin Pract CME 63(1):19–26CrossRef
70.
Keen RW (2013) Sclerosing and displastic bone diseases. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. 8 edn, Wiley, Ames, section VIII, pp 767–842
71.
Franz-Odendaal TA, Hall BK, Witten PE (2006) Buried alive: how osteoblasts become osteocytes. Dev Dyn 235:176–190CrossRefPubMed
72.
Burger EH, Klein-Nulend J (1999) Mechanotransduction in bone—role of the lacuno-canalicular network. FASEB J 13(Suppl):S101–112PubMed
73.
Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y, Hurley M, Guo C, Boskey A, Sun L, Harris SE, Rowe DW, Ke HZ, Wu D, Liu LX (2005) Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 37:945–952CrossRefPubMed
74.
75.
Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metabolism 5:464–475CrossRefPubMed
76.
Moriishi T, Fukuyama R, Ito M, Miyazaki T, Maeno T, Kawai Y, Komori H, Komori T (2012) Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading. PLoS ONE 7(6):e401–443CrossRef
77.
Bonewald LF (2007) Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci 1116:281–290CrossRefPubMed
78.
Kneissel M (2009) The promise of sclerostin inhibition for the treatment of osteoporosis. IBMS BoneKEy 6:259–264CrossRef
79.
Dalla SL, Bonewald LF (2010) Dynamics of the transition from osteoblast to osteocyte. Ann N Y Acad Sci 1192:437–443CrossRef
80.
Guo D et al (2006) Identification of proteins involved in cytoskeletal rearrangement, anti-hypoxia and membrane channels in osteocytes over osteoblasts. J Bone Miner Res 21:S168
81.
Gentili C, Cancedda R (2009) Cartilage and bone extracellular matrix. Curr Pharm Des 15:1334–1348CrossRefPubMed
82.
Robey PG, Boskey AL. The composition of bone. In: Primer on the bone metabolic diseases and disorders of mineral metabolism. Seventh ed. Official publication of the American Society for Bone and Mineral Research Ch. 6 pp. 32–38
83.
Rossert J, de Crombrugghe B (1996) Type I collagen: structure, synthesis, and regulation. In: JP Bilezikian, Raisz LC, Rodan Ga (eds) Principle of bone biology. 1st edn. Ch. 10 pp. 127–142
84.
Lian JB, Stein GS (2006) The cells of bone. In: Seibel MJ, Robins S, Bilezikian JP (eds) Dynamics of bone and cartilage metabolism. Academic, San Diego
85.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469PubMedCentralCrossRefPubMed
Metadaten
Titel
Taxonomy of rare genetic metabolic bone disorders
verfasst von
L. Masi
D. Agnusdei
J. Bilezikian
D. Chappard
R. Chapurlat
L. Cianferotti
J.-P. Devolgelaer
A. El Maghraoui
S. Ferrari
M. K. Javaid
J.-M. Kaufman
U. A. Liberman
G. Lyritis
P. Miller
N. Napoli
E. Roldan
S. Papapoulos
N. B. Watts
M. L. Brandi
Publikationsdatum
01.10.2015
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 10/2015
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3188-9

Weitere Artikel der Ausgabe 10/2015

Osteoporosis International 10/2015 Zur Ausgabe

Original Article

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

Original Article

Marrow adiposity assessed on transiliac crest biopsy samples correlates with noninvasive measurement of marrow adiposity by proton magnetic resonance spectroscopy (1H-MRS) at the spine but not the femur

Original Article

Use of proton pump inhibitors is associated with fractures in young adults: a population-based study

Original Article

Vertebral Scheuermann’s disease in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over

Original Article

Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta

Original Article

Effect of whole body vibration training on bone mineral density and bone quality in adolescents with Down syndrome: a randomized controlled trial

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

16.04.2024 | Spondylitis ankylosans | Nachrichten

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!
weitere anzeigen

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise